Final report of the 5-year clinical outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold in the treatment of single de novo coronary lesions in a first-in-human study

Yizhe Wu*, Jiasheng Yin*, Jiahui Chen, Zhifeng Yao, Juaying Qian, Li Shen, Lei Ge, Junbo Ge; on behalf of the XINSORB first-in-human study

Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China

Contributions: (I) Conception and design: L Ge, J Ge; (II) Administrative support: J Qian, J Ge; (III) Provision of study materials or patients: Z Yao; (IV) Collection and assembly of data: J Chen; (V) Data analysis and interpretation: Y Wu, J Yin, L Shen; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

*These authors contributed equally to this work.

Correspondence to: Junbo Ge; Lei Ge; Li Shen. 180 Fenglin Road, Shanghai, China. Email: ge.junbo2@zs-hospital.sh.cn; ge.lei@zs-hospital.sh.cn; nt_sunny@163.com.

Background: We aimed to report the 5-year outcomes of XINSORB bioresorbable sirolimus-eluting scaffolds in the treatment of single de novo coronary lesions in a first-in-human (FIM) study. This is the final report of the long-term clinical outcomes of the study. Recent studies have shown that bioresorbable scaffolds (BRSs) increase the risks of late target lesion failure (TLF) and thrombosis.

Methods: In this prospective, single-arm study, eligible patients with single de novo coronary lesions were enrolled and treated with XINSORB scaffolds. The scaffolds measured 3.0 mm in diameter and 12, 15, and 18 mm in length. The clinical endpoints included TLF [cardiac death, target vessel-related myocardial infarction (TV-MI), or ischaemia-driven target lesion revascularization (ID-TLR)], its components, major adverse cardiac events (MACE), and scaffold thrombosis.

Results: From September 2013 to January 2014, 30 patients were enrolled and treated with XINSORB scaffolds. The procedure had a 100% success rate. None of the patients died during the 5 years of follow-up. The primary endpoint of TLF occurred in 4 patients (13.3%). Six patients were recanalized by intervention, including 4 by ID-TLR. The rate of MACE was 16.7% (5/30). One very late case of scaffold thrombosis was recorded, which led to TV-MI. No more cases of thrombosis were recorded beyond 2 years of follow-up. The rates of clinical endpoints remained steady with no changes after 3 years of follow-up.

Conclusions: Considering that this FIM study was launched at an early stage of the BRS era and without optimal implantation techniques, the clinical outcomes of TLF during the 5-year follow-up were acceptable. The rate of thrombosis was relatively low.

Keywords: Coronary artery disease; percutaneous coronary intervention (PCI); bioresorbable scaffold (BRS)

doi: 10.21037/atm-20-5668
View this article at: http://dx.doi.org/10.21037/atm-20-5668

Introduction

Despite the considerable achievements that have been made with the use of bioresorbable scaffolds (BRSs) in the last decade, results reported recently have raised concerns regarding the long-term risks of target lesion failure (TLF) and thrombosis (1-3). However, a recently published meta-analysis indicated that this device had favourable rates of TLF and thrombosis beyond 3 years after the index procedure (4). Compared to Absorb BRS, XINSORB BRS (Shandong Huaan, China) is a contemporary scaffold.
Wu et al. Five-year outcomes of XINSORB BRS in a FIM study

The first clinical trial regarding to BRS in China was the XINSORB first-in-human (FIM) study. The FIM study on XINSORB BRS commenced in September 2013. The 6-month angiographic and clinical results of this study were reported previously (5). The in-segment late luminal loss (LLL) was 0.13±0.24 mm. No clinical events occurred during the 6-month follow-up. The randomized control trial (RCT) and registry trial of XINSORB BRS were carried out in September 2014. The results of the 1- and 3-year follow-ups have been confirmed and were promising compared with those of a commercialized metallic sirolimus-eluting stent (6). Consequently, the XINSORB BRS was approved for use in the Chinese market by the China Food and Drug Administration (CFDA) in March 2020. Here, we present our latest analysis of the 5-year clinical outcomes of the XINSORB FIM study. This is the final report of this study.

We present the following article in accordance with the TREND reporting checklist (available at http://dx.doi.org/10.21037/atm-20-5668).

Methods

Study device

XINSORB BRS is composed of poly-L-lactic acid (PLLA). The scaffold’s design is similar to that of the Absorb scaffold. The struts are coated with poly-D-L-lactic acid (PDLLA) mixed with PLLA carrying sirolimus. The dose of sirolimus ranges from 8–16 μg/mm, depending on the length of the scaffold. The struts are 160 μm in thickness. The XINSORB scaffolds used in this study measured 3.0 mm in diameter and 12, 15, and 18 mm in length.

Study design, patient population, intervention, and follow-up

This FIM study was a single-arm, prospective clinical trial. The study complied with the CFDA’s Good Clinical Practice guidelines. All procedures performed in this study involving human participants were in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by institutional ethics committee of Zhongshan Hospital, Fudan University (No. 2013-36) and informed consent was taken from all the patients. The study was performed in two centres in China. The protocol was described previously (5).

Briefly, patients were eligible if they were aged between 18–75 years old and diagnosed with stable or unstable ischaemic coronary disease or subacute myocardial infarction (beyond 7 days with normal troponin, and creatine kinase and its MB isoenzyme). Single, de novo lesions in a native coronary artery were included and was visually assessed to be <14 mm in length. The reference vessel diameter of the target lesion was 3.0 mm, and the percentage of the diameter was 50–99%, with a thrombolysis in myocardial infarction (TIMI) flow grade of >1.

The procedure was performed as standard. Predilation was mandatory, while postdilation was recommended. If postdilation was necessary, the diameter of the noncompliance balloon needed to be shorter than the implanted scaffold and up to a maximum of 0.25 mm larger. If bailout stenting was required, commercialized metallic drug-eluting stents were used.

All patients received regular clinical follow-up examinations at 30, 90, 180, and 270 days, and at 1, 2, 3, 4, and 5 years. At 180 days after the index procedure, the patients underwent angiography according to the protocol. Follow-up examinations up to 5 years were completed at the time of the current report. The patients were prescribed clopidogrel for at least 12 months, and continued taking aspirin for the duration of the study.

Endpoints and definitions

The primary endpoint of the FIM study was angiographic in-segment LLL at the 6-month follow-up, which was defined as the difference in the minimal luminal diameter from postprocedure to 6 months. Restenosis was defined as ≥50% diameter stenosis in every stented segment and peri-scaffold segment. Device success was defined as the successful delivery and deployment of the study device at the intended target lesion to obtain a final residual stenosis of <50%, as measured by quantitative coronary angiography. Bailout stenting was not regarded as a failure of the device. Other secondary endpoints included TLF [cardiac death, target vessel-related myocardial infarction (TV-MI), or ischaemia-driven target lesion revascularization (ID-TLR)], target vessel failure [TVF; cardiac death, MI, or ischaemia-driven target vessel revascularization (ID-TVR)], and major adverse cardiac events (MACE; cardiac death, MI, or ID-TLR), along with the individual component endpoints of these endpoints and device thrombosis. Device thrombosis was defined as acute (<24 hours), subacute (1–30 days), late (30 days–1 year), and very late (beyond 1 year), and the level of evidence (definite or probable) was determined according
to the Academic Research Consortium definitions (7). All clinical events were monitored by an independent clinical events committee.

**Statistical analysis**

All analyses were performed according to the intention-to-treat (ITT) principle. Continuous variables are presented as the mean ± SD. Normally distributed continuous variables were compared by Student’s t-test. All statistical analyses were two-sided and performed with the significance level set at 0.05. SAS software, version 9.4 (SAS Institute, Cary, North Carolina) was used to perform all statistical analyses.

### Results

**Patients and baseline characteristics**

Thirty eligible patients in two centres were enrolled in this study between September 2013 and January 2014, there were 19 patients from Zhongshan Hospital Fudan University and 11 patients from 301 Hospital. Informed consent was obtained from all patients before participation in the study. The patients’ baseline demographic and procedural information is shown in Table 1. Each of the 30 study devices was implanted successfully. Only one patient received bailout stenting due to distal edge dissection. All lesions were classified as ACC/AHA lesion classification.
More than 50% of the lesions were located on the left anterior descending branch. All lesions were predilated. The majority of the lesions were postdilated with a noncompliance balloon at a high pressure. All patients were discharged with no clinical events.

**Long-term follow-up and clinical outcomes**

*Figure 1* shows the patient flow chart of this study. Two patients declined invasive follow-up at 6 months. The patient who received bailout stenting underwent angiography at 6 months but was not included in the angiographic report. Consequently, the per-treatment-evaluation population comprised 27 patients, all of whom were clinically followed for 4 years. At 5 years, 4 patients were lost to follow-up after not answering the phone calls.

At 337 days after the index procedure, 1 patient suffered nontarget vessel Q wave myocardial infarction and received additional intervention. Four patients underwent TVR at the 2-year follow-up, including 3 patients with ID-TLR. Two of these patients experienced recurrent chest pain at 612 and 665 days. Repeat angiography showed restenosis at the XINSORB scaffold-treated sites, and metallic stents were implanted. The third patient experienced chest pain onset leading to non-Q-wave myocardial infarction 530 days after the index procedure. An electrocardiogram after admission to the hospital showed ST-segment elevation. An emergent angiogram was carried out immediately, revealing extensive in-scaffold thrombosis with a TIMI flow of grade 3. Optical coherent tomography (OCT) revealed scaffold discontinuity with white thrombosis. The treatment involved the placement of a metallic stent to cover the implanted scaffold. (*Figure 2*) At the 3-year follow-up, 1 more case of ID-TLR was recorded. This patient presented with chest discomfort and was admitted to the hospital 835 days after the index procedure. Restenosis was discovered, and reintervention was carried out. All 5 cases of TVF were revascularized by percutaneous coronary intervention (PCI). The follow-up continued, and no more clinical events were reported from 3–5 years. No cardiac deaths occurred during observation. *Table 2* contains detailed information on the clinical outcomes. *Figure 3* showed the Kaplan-Meier survival curve of TLF, MACE, scaffold thrombosis, and all-cause death through 5 years follow-up in this FIM study.
Device thrombosis

Only one very late, confirmed case of thrombosis was recorded at the 5-year follow-up (at exactly 530 days) in this study. This case is described in detail in the text above. No further events related to thrombosis were recorded from 2–5 years.

Typical case

Twenty-eight patients routinely also received a 6-month invasive follow-up protocol, and 3 patients underwent an additional voluntary angiographic examination at 2 or 3 and 5 years without selection. No clinical symptoms were experienced by these patients. We previously reported 5 years of serial intravascular imaging outcomes of XINSORB BRS (8). This report was the first XINSORB FIM study. The first case was a 35-year-old man with limited risk factors for atherosclerotic heart disease. Severe narrowing of the distal right coronary artery was revealed by angiography. After predilation, a 3.0×18 mm XINSORB scaffold was deployed. Repeat angiogram showed no residual stenosis and grade 3 TIMI flow. The patient was admitted for angiographic follow-up at 6 months and at 2, 3, and 5 years after the index procedure. Angiography showed a widely patent lumen at the treated site. Over time, strut “boxes” become progressively smaller and less clear under OCT, reflecting material resorption. Some “black boxes” could still be seen at the 5-year follow-up, although most struts were absorbed. The second case was a 51-year-old man with hypertension. Angiography detected severe stenosis at the middle of the circumflex artery. The patient was treated with a XINSORB scaffold measuring 3.0×18 mm. The lumen remained patent for over 5 years, as shown by angiograms. OCT showed that all struts had completely disappeared at the 5-year follow-up. The final case was a 45-year-old man with hypertension and diabetes mellitus, who was also a smoker. Angiography showed a single lesion proximal to the left anterior descending artery. A XINSORB scaffold of 3.0×15 mm was implanted. The results were similar to those in the previous case. The struts were completely absorbed, with a patent lumen. Figure 4 shows the angiograms and OCT images of cases 2 and 3.
Table 2 The 5-year clinical outcomes of the intention-to-treat population (N=30)

<table>
<thead>
<tr>
<th>Follow-up time</th>
<th>6-M</th>
<th>1-Y</th>
<th>2-Y</th>
<th>3-Y</th>
<th>4-Y</th>
<th>5-Y</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients followed</td>
<td>30</td>
<td>30</td>
<td>30</td>
<td>30</td>
<td>30</td>
<td>26</td>
</tr>
<tr>
<td>Composite endpoints</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TVF (%)</td>
<td>0</td>
<td>0</td>
<td>4 (13.3)</td>
<td>5 (16.7)</td>
<td>5 (16.7)</td>
<td>5 (16.7)</td>
</tr>
<tr>
<td>MACE (%)</td>
<td>0</td>
<td>1 (3.3)</td>
<td>4 (13.3)</td>
<td>5 (16.7)</td>
<td>5 (16.7)</td>
<td>5 (16.7)</td>
</tr>
<tr>
<td>TLF (%)</td>
<td>0</td>
<td>0</td>
<td>3 (10.0)</td>
<td>4 (13.3)</td>
<td>4 (13.3)</td>
<td>4 (13.3)</td>
</tr>
<tr>
<td>Cardiac death of MI (%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Individual component endpoints</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All-cause death (%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Cardiac death (%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>All MI (%)</td>
<td>0</td>
<td>1 (3.3)</td>
<td>2 (6.7)</td>
<td>2 (6.7)</td>
<td>2 (6.7)</td>
<td>2 (6.7)</td>
</tr>
<tr>
<td>Q-wave MI (%)</td>
<td>0</td>
<td>1 (3.3)</td>
<td>1 (3.3)</td>
<td>1 (3.3)</td>
<td>1 (3.3)</td>
<td>1 (3.3)</td>
</tr>
<tr>
<td>Non-Q-wave MI (%)</td>
<td>0</td>
<td>0</td>
<td>1 (3.3)</td>
<td>1 (3.3)</td>
<td>1 (3.3)</td>
<td>1 (3.3)</td>
</tr>
<tr>
<td>TV-MI (%)</td>
<td>0</td>
<td>0</td>
<td>1 (3.3)</td>
<td>1 (3.3)</td>
<td>1 (3.3)</td>
<td>1 (3.3)</td>
</tr>
<tr>
<td>Q-wave MI (%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Non-Q-wave MI (%)</td>
<td>0</td>
<td>0</td>
<td>1 (3.3)</td>
<td>1 (3.3)</td>
<td>1 (3.3)</td>
<td>1 (3.3)</td>
</tr>
<tr>
<td>All MI (%)</td>
<td>0</td>
<td>1 (3.3)</td>
<td>5 (16.7)</td>
<td>6 (20.0)</td>
<td>6 (20.0)</td>
<td>6 (20.0)</td>
</tr>
<tr>
<td>Q-wave MI (%)</td>
<td>0</td>
<td>1 (3.3)</td>
<td>4 (13.3)</td>
<td>5 (16.7)</td>
<td>5 (16.7)</td>
<td>5 (16.7)</td>
</tr>
<tr>
<td>Non-Q-wave MI (%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>All revascularization (%)</td>
<td>0</td>
<td>0</td>
<td>4 (13.3)</td>
<td>5 (16.7)</td>
<td>5 (16.7)</td>
<td>5 (16.7)</td>
</tr>
<tr>
<td>ID revascularization (%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Non-ID revascularization (%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>All TVR (%)</td>
<td>0</td>
<td>0</td>
<td>4 (13.3)</td>
<td>5 (16.7)</td>
<td>5 (16.7)</td>
<td>5 (16.7)</td>
</tr>
<tr>
<td>ID-TVR (%)</td>
<td>0</td>
<td>0</td>
<td>4 (13.3)</td>
<td>5 (16.7)</td>
<td>5 (16.7)</td>
<td>5 (16.7)</td>
</tr>
<tr>
<td>Non-ID-TVR (%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>All TLR (%)</td>
<td>0</td>
<td>0</td>
<td>3 (10.0)</td>
<td>4 (13.3)</td>
<td>4 (13.3)</td>
<td>4 (13.3)</td>
</tr>
<tr>
<td>ID-TLR (%)</td>
<td>0</td>
<td>0</td>
<td>3 (10.0)</td>
<td>4 (13.3)</td>
<td>4 (13.3)</td>
<td>4 (13.3)</td>
</tr>
<tr>
<td>Non-ID-TLR (%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Device thrombosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All (%)</td>
<td>0</td>
<td>0</td>
<td>1 (3.3)</td>
<td>1 (3.3)</td>
<td>1 (3.3)</td>
<td>1 (3.3)</td>
</tr>
<tr>
<td>Definite (%)</td>
<td>0</td>
<td>0</td>
<td>1 (3.3)</td>
<td>1 (3.3)</td>
<td>1 (3.3)</td>
<td>1 (3.3)</td>
</tr>
<tr>
<td>Probable (%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Acute (≤1 day) (%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Subacute (1–31 days) (%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Late (&gt;365 days) (%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Very late (&gt;365 days) (%)</td>
<td>–</td>
<td>–</td>
<td>1 (3.3)</td>
<td>1 (3.3)</td>
<td>1 (3.3)</td>
<td>1 (3.3)</td>
</tr>
</tbody>
</table>

TVF, target vessel failure; MACE, major adverse cardiac event; TLF, target lesion failure; MI, myocardial infarction; TV-MI, target vessel-related myocardial infarction; ID, ischaemia-driven; TVR, target vessel revascularization; TLR, target lesion revascularization.
Discussion

The main findings of this study were as follows: (I) considering that this FIM study was launched at an early stage of the BRS era without optimal implantation techniques, the clinical outcomes including TLF, MACE, and ID-TLR in the 5-year follow-up were acceptable; (II) no clinical events were recorded beyond 3 years; and (III) the rate of thrombosis was relatively low.

The long-term results up to 3 years showed that the rates of TLF and device thrombosis with Absorb BRS were significantly higher than those with the everolimus-eluting stent (EES) (1,2). The 3-year outcomes of the ABSORB II study showed that the rates of TLF and device thrombosis were 10% and 3% with Absorb BRS, respectively; these rates were significantly higher than those with the EES (5% and 0%, respectively). Similarly, the 3-year results from the ABSORB III study demonstrated that the rate of device thrombosis with Absorb BRS was significantly greater than that with the EES (2.3% vs. 0.7%, P=0.01), although the rate of TLF was comparable between the two devices (13.4% vs. 10.4%, P=0.055). However, Stone et al. indicated that the period of excess risk for the first generation of BRSs might end after 3 years. In a recently published meta-analysis (4), TLF occurred in 11.6% of the Absorb BRS-treated patients vs. 7.9% of the EES-treated patients between 0–3 years (HR, 1.42; 95% CI, 1.12–1.80), and in 4.3% of the BVS-treated patients vs. 4.5% of the EES-treated patients between 3–5 years (HR, 0.92; 95% CI, 0.64–1.31). Device thrombosis occurred in 2.4% of the Absorb BRS-treated patients vs. 0.6% of the EES-treated patients between 0–3 years (HR, 3.86; 95% CI, 1.75–8.50) and 0.1% of the
Figure 4 Long-term results of two typical cases in the XINSORB FIM study. One was a 51-year-old man with severe stenosis at the middle of the circumflex artery (A, white arrow). A XINSORB scaffold measuring 3.0×18 mm was implanted (E). The lumen remained patent for over 5 years (F,G,H). OCT showed that all struts gradually absorbed and completely disappeared at the 5-year follow-up (B,C,D). The other case was a 45-year-old man with a single lesion proximal to the left anterior descending artery (I, white arrow). A XINSORB scaffold of 3.0×15 mm was deployed (M). The struts were completely absorbed (J,K,L), with a patent lumen (N,O,P). Between the white lines was the implanted scaffolds. FIM, first-in-human; OCT, optical coherent tomography.
The results of this FIM study were similar to those of pooled ABSORB serial studies. Before 3 years, the rates of TLF and thrombosis were clearly increased among the BRS-treated patients; however, after 3 years, the rates of these adverse events remained steady. The results from this FIM study constitute new evidence that supports the favourable long-term outcomes of BRSs after the 3-year follow-up. The XINSORB FIM study was initiated at the early stage of the BRS era. Technologies such as intravascular imaging and optimal implantation were not utilized in the study; however, they are now considered standard processes in today’s practice of BRS implantation. During the 3-year follow-up, the rates of TLF and thrombosis were slightly increased. Most device failures were attributable to restenosis, leading to ischaemia and revascularization. It is possible that it took up to 3 years for the first generation of BRSs to be fully absorbed. After complete absorption, the natural vessel wall was restored, with limited inflammation (9,10). The rates of device failure and clinical events could continue to increase before the vessel wall was completely repaired. The results from the meta-analysis and our study matched those obtained from the preclinical study. Vessel wall inflammation and repair play pivotal roles in clinical outcomes.

Most adverse events were attributed to the relatively thick struts of the first generation of BRSs, which required adequate mechanical properties. The optimal device implantation technique was also central to obtaining acute and long-term outcomes. However, during the absorption process of BRSs, a unique failure mode known as intraluminal scaffold dismantling can occur (11-13). In our study, the case of thrombosis was caused by strut discontinuity or fracture, which was one of the negative consequences of bulk erosion. Another failure mode of BRSs is neoatherosclerosis (14). In this study, we reviewed 4 cases of TLR. Two of these cases suffered ischaemic symptoms from restenosis. OCT showed neoatherosclerosis at the previously stented site. However, the mechanism of neoatherosclerosis in BRS is still unknown.

After the implantation of coronary devices, maintaining drug therapy, including statins and anti-platelet agents, for a lifetime is crucial to inhibiting neointima hyperplasia and reducing thrombosis. However, it is unknown for how long dual antiplatelet therapy (DAPT) should be administered to patients with BRSs. Thicker struts have a clearly thrombogenic effect (15). Furthermore, the PLLA nature of the BRS limits sizing and implantation technology to prevent fracture, underexpansion, or incomplete apposition, which might lead to delayed healing or floating struts into the lumen (16-18). The current recommendation suggests that the duration of DAPT treatment should be prolonged until the BRS is completely resorbed (19). In a much earlier XINSORB FIM study, patients were prescribed aspirin and clopidogrel for at least 12 months. However, in later RCTs of XINSORB, the duration of DAPT was modified. In fact, 59% of the XINSORB-treated patients in the XINSORB RCT were still on DAPT at the 3-year follow-up.

Along with BRS came a concept called vascular restoration therapy (VRT). BRS supports the vessel wall, resisting acute occlusion after implantation until negative remodeling is terminated. It can be resorbed and, subsequently, the vessel can be released from the perpetual caging of metallic stents. However, VRT is a complex process in which safe BRS implantation should be the first step. A systemic treatment targeted to the underlying chronic disease would be necessary to ameliorate omnipresent endothelial dysfunction demonstrated in patients with coronary risk factors and atherosclerosis.

This study has some limitations. First, the sample size was extremely small. Only 30 patients were enrolled in this FIM study. However, this study was designed to investigate the preliminary safety and efficacy of XINSORB BRS. According to the guidelines of the CFDA, 30 patients constitutes a reasonable sample size, and no control group was needed. Second, this study did not use intravascular imaging. The importance of invasive imaging modalities, from angiography to sound- and light-based techniques, in guiding BRS implantation procedures and assessing the acute results post implantation as well as the long-term changes until complete resorption, has been proven (20). However, the importance of these imaging techniques was not emphasized at the beginning of the BRS era. Early studies, including this study and the ABSORB China study, neither recommended nor encouraged these methods, even in the protocols. Third, optimal implantation techniques, such as the PSP technique (proper lesion preparation, vessel sizing, and postdilation with high pressure), are recommended to improve the long-term outcomes of BRS implantation; however, these techniques were not used in this FIM study (19). Although the rates of predilation and postdilation were 100% and 90%, respectively, the diameter of the balloon was 2.5 mm in most cases of predilation.
Visualization was used for sizing instead of QCA or other intravascular imaging techniques. The study design also had limitations. Fourth, the lesions treated in this FIM study were fairly simple. The experience acquired from this study could not be extrapolated to more complex lesions. Finally, the scaffold used in this study was a first-generation BRS, which meant thicker struts, a large profile, low deliverability, and poor compliance with high risks of restenosis and thrombosis. The next generation of BRSs with favourable expansion properties and minimal recoil has been developed. Improved 3-year results with a 100 μm PLLA-based BRS have been reported (21). If newly designed BRSs can achieve comparable results to those of traditional metallic stents during the active bioresorption phase, BRS technology might be a suitable option for many patients with coronary artery disease.

Conclusions

Considering that this FIM study was launched at an early stage of the BRS era and did not use optimal implantation techniques, the clinical outcomes of TLF during the 5-year follow-up were acceptable. The rate of thrombosis was relatively low.

Acknowledgments

Funding: This work was funded by grants from the National Natural Science Foundation of China (Nos. 81521001 and 81670319) and the National Key Research and Development Program (Nos. 2016YFC1102300 and 2016YFC1102303).

Footnote

Reporting Checklist: The authors have completed the TREND reporting checklist. Available at http://dx.doi.org/10.21037/atm-20-5668

Data Sharing Statement: Available at http://dx.doi.org/10.21037/atm-20-5668

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-20-5668). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All procedures performed in this study involving human participants were in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by institutional ethics committee of Zhongshan Hospital, Fudan University (No. 2013-36) and informed consent was taken from all the patients.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

3. Tijssen RYG, Kraak RP, Hofma SH, et al. Complete two-year follow-up with formal non-inferiority testing on primary outcomes of the AIDA trial comparing the Absorb bioresorbable scaffold with the XIENCE drug-eluting metallic stent in routine PCI. EuroIntervention 2018;14:e426-33.


(English Language Editor: J. Reynolds)